|
|
|
RLYP - Relypsa, Inc.
Relypsa, Inc. (RLYP) was a biopharmaceutical company that developed and marketed treatments for patients with renal and cardiovascular diseases. However, it's important to note that Relypsa, Inc. is no longer an active publicly traded company.
The company was acquired by Galenica Group in 2016, and the combined entity now operates as Vifor Pharma Group. At the time of the acquisition, the market capitalization of Relypsa, Inc. was approximately $1.53 billion.
Prior to the acquisition, Relypsa, Inc. developed a product called Veltassa, which was used to treat hyperkalemia, a condition characterized by high levels of potassium in the blood. The company also had a pipeline of products in development for the treatment of other renal and cardiovascular conditions.
Overall, while Relypsa, Inc. is no longer an active publicly traded company, its legacy can be seen in the continued development and availability of innovative treatments for renal and cardiovascular diseases by its successor, Vifor Pharma Group.
|
|
|
|
|
